Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: Results of an open-label, single-arm, multicentre pilot study

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 8, 2008, Pages 923-930

  Huang, P H ^b   Liao, Y H ^a   Wei, C C ^c   Tseng, Y H ^a   Ho, J C ^b   Tsai, T F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c Chung Shan University Hospital   (Taiwan)

Author keywords

Alefacept; Asian; Biologics; Clinical trial; Pilot; Psoriasis

Indexed keywords

ALEFACEPT; CORTICOSTEROID; EMOLLIENT AGENT;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; ASIA; BODY SURFACE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CEREBROVASCULAR ACCIDENT; CHINESE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MALAISE; MALE; MOUTH ULCER; MUSCULOSKELETAL DISEASE; MYALGIA; PILOT STUDY; POLYARTHRITIS; POPULATION; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RASH; SORE THROAT; TAIWAN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; RECOMBINANT FUSION PROTEINS; SAFETY; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME;

EID: 52249110434     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02575.x     Document Type: Article

References (33)

1. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis. epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005 64 (Suppl. 2 ii18 ii23.
2. Bowcock AM, Krueger JG. Getting under the skin. the immunogenetics of psoriasis. Nature Rev Immunol 2005 5 : 699 711.
3. Lebwohl M, Christophers E, Langley R et al. Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003 139 : 719 727.
4. Moingeon P, Chang HC, Wallner BP et al. CD2-mediated adhesion facilities T lymphocyte antigen recognition function. Nature 1989 339 : 312.
5. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New Engl J Med 2001 345 : 248 255.
6. van de Kerkhof P, Griffiths CE, Christophers E, Lebwohl M, Krueger GG. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology 2005 211 : 256 263.
7. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004 150 : 317 326.
8. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003 17 (Suppl. 2 17 24.
9. Ortonne JP. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003 17 (Suppl. 2 12 16.
10. Krueger GG, Papp KA, Stough DB et al. Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 47 : 821 833.
11. Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005 53 : 73 75.
12. Koo JY, Bagel J, Sweetser MT, Ticho BS. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol 2006 5 : 623 628.
13. Goffe B, Papp K, Gratton D et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005 27 : 1912 1921.
14. Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006 54 : 61 63.
15. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984 10 : 965 968.
16. Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the National Skin Centre (Singapore) from 1989 to 1990. Int J Dermatol 1992 31 : 555 559.
17. Tsai TF. Current status and prospect for psoriasis treatment in Taiwan. Dermatol Sinica 2005 23 : 69 80.
18. Tsai TF, Hu CY, Tsai WL et al. HLA-Cw6 specificity and polymorphic residues are associated with susceptibility among Chinese psoriatics in Taiwan. Arch Dermatol Res 2002 294 : 214 220.
19. Gudjónsson JE, Kárason A, Antonsdóttir AA et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002 118 : 362 365.
20. Gudjonsson JE, Karason A, Runarsdottir EH et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006 126 : 740 745.
21. Chen HS, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatol Sinica 2003 21 : 216 224.
22. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004 50 : 859 866.
23. Papp KA, Henninger E. Safe psoriasis control. a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment. J Cutan Med Surg 2005 9 : 276 283.
24. Ashcroft D, Li Wan Po A, Williams H, Griffiths C. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999 141 : 185 191.
25. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 244.
26. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment and lattice system physician's global assessment. J Am Acad Dermatol 2004 51 : 563 569.
27. Callan JP, Krueger GG, Lebwohl M et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003 49 : 897 899.
28. Ellis CN, Mordin MM, Adler EY. Randomized, placebo-controlled phase II trial. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003 4 : 131 139.
29. Finlay AY, Salek MS, Haney J for the Alefacept Clinical Study Group. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003 206 : 307 315.
30. Ortonne JP, Lebwohl M, Em Griffiths C for the Alefacept Clinical Study Group. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003 13 : 117 123.
31. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A for the Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003 139 : 1563 1570.
32. Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004 22 : 407 426.
33. Chamian F, Lin SL, Lee E et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med 2007 5 : 27.